RE:Discovery Program...I am also curious about the discovery program.
Sure hope it's around Ketorolac.
That would explain a lot of things right now.
Regardless - to your point, likely makes no difference to share price.
Needle moves on OTENA's success in P2 (or on P2 expectations).
Hoping that partnering or an acquisition revolves around OTENA only.
Just not worth negotiating anything else until the funnel drugs are proven.
IMO